文献速递心脑血管急症重症综合管理与镇静镇痛

比较4F-PCC与aPCC在口服抗凝药相关颅内出血中的给药时间与结局

Comparison of 4F-PCC and aPCC time to administration and outcomes for oral anticoagulant-related ICH.
PubMed 文献 · Am J Emerg Med · 2022-03-24
一句话结论口服抗凝药相关颅内出血患者中,4F-PCC与aPCC给药时间无显著差异,仅CT出结果时间与给药延迟(>60 min)相关。

这项多中心回顾性队列图表审查纳入350份病历中的193例口服抗凝药相关颅内出血患者(4F-PCC组99例、aPCC组94例),比较两种凝血酶原复合物浓缩物的给药时间与结局。主要终点中位给药时间4F-PCC组141分钟(IQR 93-185) vs aPCC组121分钟(IQR 107-194;p=0.08),无显著差异。所有次要终点(死亡率、改良Rankin量表评分、首次CT后6小时复查CT血肿体积恶化、住院与ICU住院时长)两组间均无差异。仅CT出结果时间是给药延迟(>60 min)的危险因素(OR 1.160;95%CI 1.073-1.255;p<0.001)。作者认为需更多前瞻性随机对照试验确定理想逆转时间以改善患者结局。

要点

  • 口服抗凝药相关颅内出血患者中,4F-PCC组中位给药时间141分钟(IQR 93-185) vs aPCC组121分钟(IQR 107-194),差异无统计学意义(p=0.08)。
  • 两组死亡率、改良Rankin量表评分、首次CT后6小时复查CT血肿体积恶化、住院与ICU住院时长均无差异。
  • 仅CT出结果时间是给药延迟(>60 min)的危险因素(OR 1.160;95%CI 1.073-1.255;p<0.001)。
  • 作者认为需更多前瞻性随机对照试验确定理想逆转时间以改善患者结局。

适用人群与场景

  • 服用口服抗凝药并发生颅内出血、接受4F-PCC或aPCC逆转的患者;研究为多中心回顾性队列图表审查,覆盖两年期间。

研究设计与关键结果

  • 研究设计:多中心、回顾性队列图表审查,纳入350份病历中的193例(4F-PCC组n=99,aPCC组n=94)。
  • 主要终点:中位给药时间4F-PCC组141分钟(IQR 93-185) vs aPCC组121分钟(IQR 107-194),差异无统计学意义(p=0.08)。
  • 次要终点:死亡率、改良Rankin量表评分、首次CT后6小时复查CT血肿体积恶化、住院与ICU住院时长两组均无差异。
  • 三级终点:仅CT出结果时间是给药延迟(>60 min)的危险因素(OR 1.160;95%CI 1.073-1.255;p<0.001)。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列图表审查。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于口服抗凝药相关颅内出血患者,4F-PCC与aPCC在给药时间上无显著差异,临床选择可能不受给药速度影响。
  • CT出结果时间是给药延迟(>60 min)的危险因素,提示优化CT流程可能缩短给药时间。
  • 作者认为需更多前瞻性随机对照试验确定理想逆转时间以改善患者结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Intracranial hemorrhages (ICHs) are associated with increased morbidity and mortality. Use of oral anticoagulants are a potential risk factor for ICH, and reversal of the anticoagulant with agents such as Four-Factor Prothrombin Complex Concentrate (4F-PCC) or Activated Prothrombin Complex Concentrate (aPCC) is vital to prevent hematoma expansion. The objective of the study was to the compare the time to administration and outcomes of 4F-PCC or aPCC in patients with ICH taking an oral anticoagulant.

METHODS: This was a multicenter, retrospective cohort chart review of patients with ICH taking an oral anticoagulants who received 4F-PCC or aPCC over a two year period. The primary outcome of the study was to the compare the time to administration of 4F-PCC or aPCC in patients with ICH on an oral anticoagulant. Secondary outcomes included evaluating mortality rate, modified Rankin scale (mRs) score, presence of worsening bleed volume on first computed tomography (CT) six hours after the initial reading, and hospital and intensive care unit (ICU) length of stay. The tertiary outcome was to evaluate the effect of risk factors for delay on time to administration, with delay being greater than 60 min.

RESULTS: A total of 350 patient charts were reviewed and 193 patients (4F-PCC [n = 99] and aPCC [n = 94]) were included in the study. There was no significant difference in the primary outcome of median time to administration for the 4F-PCC group (141 min, IQR [93-185]) compared to aPCC (121 min, IQR [107-194]; p = 0.08). No difference was identified between the two groups for all secondary outcomes. Only time to CT results was found to be a risk factor for administration delay (OR, 1.160; 95% CI, 1.073-1.255; p < 0.001).

DISCUSSION: In patients with ICH taking oral anticoagulants, there was no significant difference in the time to administration between 4F-PCC and aPCC. More prospective randomized controlled trials are warranted to determine an ideal reversal time to improve patient outcomes.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Lin S, Cunningham B, Mullen C, et al. Comparison of 4F-PCC and aPCC time to administration and outcomes for oral anticoagulant-related ICH. Am J Emerg Med. 2022. PMID: 35405470. doi:10.1016/j.ajem.2022.03.038

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。